Correlation between the decrease of cholesterol efflux from macrophages in patients with type II diabetes mellitus and down-regulated CYP7A1 expression.

The purpose of this study was to examine the changes of cellular cholesterol efflux from macrophages in patients with type II diabetes mellitus (DM), and to determine the expression of CYP7A1, ABCG5, and LXRβ therein. We recruited 30 patients with type II DM (including 15 patients complicated with coronary heart disease and 15 patients with DM only) and 15 normal controls for this study. Peripheral blood monocytes were isolated for macrophage culture. The mRNA and protein expression levels of CYP7A1, ABCG5, and LXRβ were determined using real-time polymerase chain reaction and western blot. The macrophage cholesterol efflux rate was determined with 10% autoserum and standard serum as receptors. We determined that the expression levels of macrophage CYP7A1 mRNA and protein in the type II DM group were significantly lower than those in the control group, but no differences were found in the ABCG5 and LXRβ expression levels between the groups. The macrophage cholesterol efflux rate in the patients with type II DM was also significantly decreased compared with that of the normal control subjects (P < 0.01). Furthermore, CYP7A1 mRNA expression and macrophage cholesterol efflux rate were significantly positively correlated. In summary, this study demonstrated that the macrophage cholesterol efflux in patients with type II DM was significantly reduced, and that this reduction was associated with the down-regulation of CYP7A1 expression.

[1]  F. Pedrosa,et al.  The plasma logarithm of the triglyceride/HDL-cholesterol ratio is a predictor of low risk gestational diabetes in early pregnancy. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[2]  L. Terrazas,et al.  Alternatively Activated Macrophages in Types 1 and 2 Diabetes , 2012, Mediators of inflammation.

[3]  J. Marrs.  Glucose and Low-Density Lipoprotein Cholesterol Lowering in Elderly Patients with Type 2 Diabetes , 2012, Drugs & Aging.

[4]  A. Penfornis,et al.  LDL-cholesterol target values and actual values in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic monotherapy: the lipid results of the French ESCALADE survey. , 2012, Annales d'Endocrinologie.

[5]  S. Dinneen,et al.  Review: Quality improvement strategies reduce HbA1c, LDL cholesterol, and BP in diabetes , 2012, Annals of Internal Medicine.

[6]  Huifang Liu,et al.  Altered Polarization, Morphology, and Impaired Innate Immunity Germane to Resident Peritoneal Macrophages in Mice with Long-Term Type 2 Diabetes , 2012, Journal of biomedicine & biotechnology.

[7]  J. Cercueil,et al.  Liver fat content is associated with an increase in cholesterol synthesis independent of statin therapy use in patients with type 2 diabetes. , 2012, Atherosclerosis.

[8]  M. Buysschaert,et al.  Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels. , 2012, Journal of clinical lipidology.

[9]  S. Voros,et al.  Evaluation of low-density lipoprotein particle number distribution in patients with type 2 diabetes mellitus with low-density lipoprotein cholesterol <50 mg/dl and non-high-density lipoprotein cholesterol <80 mg/dl. , 2012, The American journal of cardiology.

[10]  O. Ganda,et al.  Quantification of concordance and discordance between apolipoprotein-B and the currently recommended non-HDL-cholesterol goals for cardiovascular risk assessment in patients with diabetes and hypertriglyceridemia. , 2012, Diabetes research and clinical practice.

[11]  R. Maranhão,et al.  Removal from the plasma of the free and esterified forms of cholesterol and transfer of lipids to HDL in type 2 diabetes mellitus patients , 2012, Lipids in Health and Disease.

[12]  N. Tada,et al.  Estimation of lipoprotein profile in patients with type II diabetes and its relevance to remnant lipoprotein cholesterol levels. , 2012, Atherosclerosis.

[13]  H. Low,et al.  Advanced glycation end-products (AGEs) and functionality of reverse cholesterol transport in patients with type 2 diabetes and in mouse models , 2012, Diabetologia.

[14]  N. Lloberas,et al.  Hepatocyte growth factor gene therapy enhances infiltration of macrophages and may induce kidney repair in db/db mice as a model of diabetes , 2012, Diabetologia.

[15]  Wen Zhang,et al.  A dual enzymatic-biosensor for simultaneous determination of glucose and cholesterol in serum and peritoneal macrophages of diabetic mice: evaluation of the diabetes-accelerated atherosclerosis risk. , 2011, Analytica chimica acta.

[16]  H. Pijl,et al.  Prolonged Caloric Restriction in Obese Patients With Type 2 Diabetes Mellitus Decreases Plasma CETP and Increases Apolipoprotein AI Levels Without Improving the Cholesterol Efflux Properties of HDL , 2011, Diabetes Care.

[17]  Y. Iwakura,et al.  IL-1 regulates the Cyp7a1 gene and serum total cholesterol level at steady state in mice. , 2009, Biochemical and biophysical research communications.

[18]  T. Osborne,et al.  Peroxisome Proliferator-activated Receptor-γ Coactivator-1α Activation of CYP7A1 during Food Restriction and Diabetes Is Still Inhibited by Small Heterodimer Partner* , 2008, Journal of Biological Chemistry.

[19]  E. Dubé,et al.  Modulation of Cholesterol Transport by Insulin-Treated Gestational Diabetes Mellitus in Human Full-Term Placenta1 , 2013, Biology of reproduction.

[20]  L. Pérez de Isla,et al.  [Prevalence of inapropriate LDL cholesterol levels in patients with coronary disease and/or type 2 diabetes]. , 2012, Revista clinica espanola.